ArticleJournal of general internal medicine2004
Hepatitis C virus infection in San Francisco's HIV-infected urban poor.
Article in Journal of general internal medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Viral blood-borne infections testing and linkage to care cascade among persons who experience homelessness in the United States: a systematic review and meta-analysis.BMC public health · 2022Pooled it
- Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review.American journal of public health · 2016Pooled it
- Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2011Pooled it
- Infectious Diseases Among People Experiencing Homelessness: A Systematic Review of the Literature in the United States and Canada, 2003-2022.Public health reports (Washington, D.C. : 1974)Pooled it
- The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.AIDS (London, England) · 2014Trial
- Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.Drug and alcohol dependence · 2010Trial
- Understanding correlates of hepatitis C virus infection among homeless recently paroled men.Journal of forensic nursingTrial
- Changes in Health-related Quality of Life for Hepatitis C Virus-Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Shelter-Based Integrated Model Is Effective in Scaling Up Hepatitis C Testing and Treatment in Persons Experiencing Homelessness.Hepatology communications · 2022Article
- Self-reported hepatitis C(HCV) testing among people living with human immunodeficiency virus (PLWH).Heliyon · 2021Article
- Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.The International journal on drug policy · 2019Article
- HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment.AIDS research and therapy · 2017Article
- HCV screening in a cohort of HIV infected and uninfected homeless and marginally housed women in San Francisco, California.BMC public health · 2017Article
- Article
- "Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign.JMIR research protocols · 2015Article
- Awareness of biologically confirmed HCV among a community residing sample of drug users in Baltimore City.Journal of community health · 2014Article
- Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.AIDS patient care and STDs · 2014Review
- The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Journal of viral hepatitis · 2013Review
- Diabetes and infections-hepatitis C: is there type 2 diabetes excess in hepatitis C infection?Current diabetes reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo measure Hepatitis C Virus (HCV) prevalence, incidence, and initiation of HCV therapy in a representative HIV-infected cohort of the urban poor.
designCohort analysis.
settingThe Research and Access to Care for the Homeless (REACH) Cohort is a systematic sample of HIV-infected marginally housed individuals identified from single-room occupancy hotels, homeless shelters, and free lunch programs in San Francisco.
participantsTwo hundred forty-nine participants with 28.9 months (median) of follow-up were studied. Mean age was 44 (range 24 to 75, standard deviation 8.4) years. Eighty-two percent were male, 43% were African-American, 64% were lifetime injection drug users, and 24% had been on the street or in a shelter in the prior month.
interventionsWe measured HCV testing and treatment history with structured interviews; additionally, participants were tested for HCV antibodies (EIA-2) with RNA viral load confirmation. MAIN
resultsAt baseline, 172 (69.1%) were HCV-positive and 182 (73.1%) were HCV-positive at follow-up, including 155 (62.2%) with viremia. HCV-positive status was associated with having injected drugs, elevated serum alanine aminotransferase, homelessness in the last 1 year, and more severe depressive symptoms. The incidence of new HCV infection was 4.63% per person-year (ppy; 95% confidence interval, 2.31 to 8.13) in the entire cohort and 16.77% ppy among injection drug users. The prevalence of HCV antibody-negative HCV-viremia was 13.2% (10/76). Nonwhites were less likely to receive HCV testing and subspecialty referral, controlled for drug use and other confounders. Sixty-eight percent (123/182) were aware treatment was available; however, only 3.8% (7/182) or 1.16% ppy received HCV treatment.
conclusionsWhile HCV infection is common, HCV treatment is rare in the HIV-HCV coinfected urban poor. Urban poor, nonwhite individuals are less likely to receive HCV testing and subspecialty referral than their white counterparts. Antibody-negative infection may complicate screening and diagnosis in HIV-infected persons. J
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.